Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025

Core Viewpoint - Haleon Plc reported a slight decline in revenue for 2024, reflecting challenges in the consumer healthcare market, particularly in cold and flu product demand [1][2]. Financial Performance - Revenue for 2024 was reported at 11.23 billion pounds (US$14.19 billion), down 0.6% compared to the previous year [1]. - Adjusted operating profit for 2024 was 2.5 billion pounds, a decrease of 6.5% at constant currency [1]. - Organic revenue growth was 5.0%, driven by a 3.7% increase in price and a 1.3% increase in volume/mix, with a notable 6.8% organic growth in Q4 [1]. Segment Performance - Oral Health revenue increased by 5.6% to 3.3 billion pounds, with organic revenue growth of 9.6% [5]. - Vitamins, Minerals, and Supplements revenue rose by 3.4% to 1.7 billion pounds, with organic growth of 7.6%, including 8.2% organic growth in Q4 [5]. - Pain Relief revenue declined by 3.3%, with flat organic growth of 0.1%, totaling 2.6 billion pounds [5]. - Respiratory Health revenue decreased by 3.4% to 1.7 billion pounds, with organic revenue growth of 0.9% [5]. - Digestive Health and Other revenue fell by 7.2% to 2 billion pounds [2]. Future Guidance - The company projects organic revenue growth for 2025 to be between 4% and 6%, with expectations for growth to be weighted towards the second half of the year [3][4]. - A foreign exchange translation headwind of approximately 1.0% and 2.5% is expected to negatively impact net revenue and adjusted operating profit [3]. Market Reaction - Haleon Plc's stock (HLN) was down 4.12% at $9.78 during the premarket session [4].